Project Grant K99AR086311
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of California, San Diego a $675,131 Project Grant effective August 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award funds research to develop ultrashort echo time (UTE) magnetic resonance imaging (MRI) techniques for early detection of knee osteoarthritis (OA). The project addresses...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Regents of the University of California, San Francisco a $219,609 Project Grant on September 5, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to develop an innovative in vitro methodology for detecting changes in bone matrix mechanical properties. The primary deliverable is the establishment and validation of a micropillar-based...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded $368,156 to the University of California, Los Angeles on June 5, 2026, for research under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This two-year project, scheduled for completion by May 31, 2028, focuses on the development and optimization of UGiGel, an innovative gelatin-based, self-healing bioadhesive designed to address...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of California, San Francisco a $545,808 Project Grant on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This project will be conducted through March 31, 2031, and focuses on developing matrix-modifying therapies to increase cartilage endplate (CEP) permeability and improve spinal disc nutrition. The...
- Federal Grant Award Summary The University of Delaware received a $1.2 million Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded on September 24, 2025, with completion targeted by August 31, 2030. This translational validation study will develop and deploy next-generation diagnostic methods for bone fracture healing using ultrashort echo time...
- Federal Project Grant Award Summary This Project Grant, awarded July 15, 2025, by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $169,344 in federal funding to the University of California, Davis through June 30, 2030. The award supports mechanistic research investigating systemic and local immunomodulation of fracture healing in polytrauma patients, addressing a...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Virginia a $685,866 Project Grant effective August 15, 2025, through July 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research initiative, titled "Leveraging Context-Specific eQTL to Inform BMD GWAS," focuses on identifying causal genes underlying bone mineral density (BMD)...
- Federal Grant Award Summary The University of California, Los Angeles received a $366,639 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), awarded September 5, 2025, with completion targeted for August 31, 2029. This award funds research to understand mechanisms driving poor outcomes in women with dermatomyositis (DM), a rare autoimmune disease that...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded the University of Delaware a $666,825 Project Grant on September 1, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the structural and functional roles of muscle-subtendon units in Achilles tendinopathy. The research will extend through June 30, 2030, utilizing advanced biomechanical sensors, magnetic resonance imaging...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded New Jersey Institute of Technology a $330,107 Project Grant effective September 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award supports fundamental research investigating the role of stress anisotropy—directional stress differences in extracellular matrices—in fibroblast activation and its...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $117,426 Project Grant to the University of California, San Diego, effective June 18, 2026, with completion by May 31, 2028. Under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), this award funds the development of a novel ultrashort echo time quantitative magnetization transfer (UTE-QMT) magnetic resonance imaging (MRI) method designed to noninvasively measure bone collagen crosslinking in Type 2 Diabetes Mellitus (T2DM) patients. The research addresses a critical clinical gap in fracture risk assessment, as current bone mineral density measurements via dual-energy X-ray absorptiometry fail to accurately predict fracture risk in diabetic populations despite preserved or elevated bone density readings. The project deliverables include development and validation of the UTE-QMT MRI technique to quantify advanced glycation end-products-induced collagen crosslinking in cortical bone, a distinctive bone quality characteristic that contributes to increased bone fragility in T2DM patients. This innovative diagnostic approach will enable improved bone health assessment and facilitate evaluation of antidiabetic drug effects on bone quality, advancing clinical management strategies for the approximately 500 million individuals globally affected by Type 2 Diabetes Mellitus.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $117.4k | 6/17/26 |